Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Fulgent Genetics, Inc. (FLGT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/23/2023 |
4
| Hsieh Ming (CEO) has filed a Form 4 on Fulgent Genetics, Inc.|
Txns:
| Disposed of 750,000 options to buy
@ $0
Acquired 750,000 options to buy
@ $0 |
|
| 08/21/2023 |
4
| Xie Jian (President and COO) has filed a Form 4 on Fulgent Genetics, Inc.|
Txns:
| Sold 1,307 shares
@ $33.8811, valued at
$44.3k
|
|
| 08/21/2023 |
4
| Kim Paul (CFO and Treasurer) has filed a Form 4 on Fulgent Genetics, Inc.|
Txns:
| Sold 491 shares
@ $33.8811, valued at
$16.6k
Sold 1,307 shares
@ $33.8811, valued at
$44.3k
|
|
| 08/21/2023 |
4
| Gao Hanlin (Chief Scientific Officer) has filed a Form 4 on Fulgent Genetics, Inc.|
Txns:
| Sold 342 shares
@ $33.8811, valued at
$11.6k
|
|
| 08/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/07/2023 |
4
| Xie Jian (President and COO) has filed a Form 4 on Fulgent Genetics, Inc.|
Txns:
| Paid exercise price by delivering 6,198 shares
@ $40.08, valued at
$248.4k
|
|
| 08/07/2023 |
4
| Kim Paul (CFO and Treasurer) has filed a Form 4 on Fulgent Genetics, Inc.|
Txns:
| Paid exercise price by delivering 1,240 shares
@ $40.08, valued at
$49.7k
|
|
| 08/04/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/04/2023 |
8-K
| Investor presentation, Quarterly results|
Docs:
|
"June 30, December 31, 2023 2022 ASSETS: Cash and cash equivalents $ 58,348 $ 79,506 Investments in marketable securities 788,466 773,377 Accounts receivable, net 34,809 52,749 Property, plant, and equipment, net 87,556 81,353 Other assets 385,398 399,068 Total assets $ 1,354,577 $ 1,386,053 LIABILITIES & EQUITY: Accounts payable, accrued liabilities and other liabilities $ 91,251 $ 116,178 Total stockholders’ equity 1,263,326 1,269,875 Total liabilities & equity $ 1,354,577 $ 1,386,053 FULGENT GENETICS, INC. Condensed Consolidated Statement of Operations Data Three and Six Months Ended June 30, 2023 and 2022 Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Revenue $ 67,853 $ 125,341 $ 134,021 $ 445,609 Cost of revenue 47,281 60,065 94,638 137,790 Gross profit 20,5...",
"2018 2019 2020 2021 2022 2017 2016" |
|
| 08/03/2023 |
4
| Xie Jian (President and COO) has filed a Form 4 on Fulgent Genetics, Inc.|
Txns:
| Paid exercise price by delivering 775 shares
@ $38.83, valued at
$30.1k
|
|
| 08/03/2023 |
4
| Hsieh Ming (CEO) has filed a Form 4 on Fulgent Genetics, Inc.|
Txns:
| Paid exercise price by delivering 4,783 shares
@ $38.83, valued at
$185.7k
|
|
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/06/2023 |
4
| Xie Jian (President and COO) has filed a Form 4 on Fulgent Genetics, Inc.|
Txns:
| Sold 1,433 shares
@ $40.2961, valued at
$57.7k
|
|
| 06/06/2023 |
4
| Kim Paul (CFO and Treasurer) has filed a Form 4 on Fulgent Genetics, Inc.|
Txns:
| Sold 1,403 shares
@ $40.2961, valued at
$56.5k
|
|
| 06/06/2023 |
4
| Gao Hanlin (Chief Scientific Officer) has filed a Form 4 on Fulgent Genetics, Inc.|
Txns:
| Sold 1,000 shares
@ $40.2961, valued at
$40.3k
|
|
| 06/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/19/2023 |
4
| Xie Jian (President and COO) has filed a Form 4 on Fulgent Genetics, Inc.|
Txns:
| Sold 1,320 shares
@ $35.4623, valued at
$46.8k
|
|
| 05/19/2023 |
4
| Kim Paul (CFO and Treasurer) has filed a Form 4 on Fulgent Genetics, Inc.|
Txns:
| Sold 921 shares
@ $35.4623, valued at
$32.7k
Sold 345 shares
@ $35.4623, valued at
$12.2k
|
|
| 05/19/2023 |
4
| Gao Hanlin (Chief Scientific Officer) has filed a Form 4 on Fulgent Genetics, Inc.|
Txns:
| Sold 345 shares
@ $35.4623, valued at
$12.2k
|
|
| 05/18/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/18/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/05/2023 |
4
| Xie Jian (President and COO) has filed a Form 4 on Fulgent Genetics, Inc.|
Txns:
| Paid exercise price by delivering 6,198 shares
@ $29.33, valued at
$181.8k
|
|
| 05/05/2023 |
4
| Kim Paul (CFO and Treasurer) has filed a Form 4 on Fulgent Genetics, Inc.|
Txns:
| Paid exercise price by delivering 865 shares
@ $29.33, valued at
$25.4k
|
|
| 05/05/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/05/2023 |
8-K
| Investor presentation, Quarterly results|
Docs:
|
"March 31, December 31, 2023 2022 ASSETS: Cash and cash equivalents $ 66,172 $ 79,506 Investments in marketable securities 805,146 773,377 Accounts receivable, net 43,549 52,749 Property, plant, and equipment, net 79,083 81,353 Other assets 382,817 399,068 Total assets $ 1,376,767 $ 1,386,053 LIABILITIES & EQUITY: Accounts payable, accrued liabilities and other liabilities $ 107,848 $ 116,178 Total stockholders’ equity 1,268,919 1,269,875 Total liabilities & equity $ 1,376,767 $ 1,386,053 FULGENT GENETICS, INC. Condensed Consolidated Statement of Operations Data Three Months Ended March 31, 2023 and 2022 Three Months Ended March 31, 2023 2022 Revenue $ 66,168 $ 320,268 Cost of revenue 47,357 77,725 Gross profit 18,811 242,543 Operating expenses: Research and development 9,782 5,989 Selling...",
"2018 2019 2020 2021 2022 2017 2016" |
|
| 05/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/02/2023 |
4
| Gao Hanlin (Chief Scientific Officer) has filed a Form 4 on Fulgent Genetics, Inc.|
Txns:
| Paid exercise price by delivering 76 shares
@ $29.57, valued at
$2.2k
|
|
| 03/31/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/31/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/31/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
|
|
|